Search Results

Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc.

Donaldson Company, Inc., a leading worldwide provider of innovative filtration products and solutions, announced it has entered into a definitive agreement allowing the Company to purchase a 49% stake in Medica S.p.A.

Enovis™ Corporation an innovation-driven, medical technology growth company, announced that it closed the acquisition of LimaCorporate S.p.A., a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions.

Quince Therapeutics, Inc. announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company.

Nemysis is pleased to announce that it has entered into a Strategic Alliance Agreement with Bruno Farmaceutici S.p.A. for the mutual advancement of the portfolio and sales of each company.

Axxam S.p.A. and Momentum Biotechnologies have announced a partnership to provide unique drug discovery solutions for biotechnology and pharmaceutical clients.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that the U.S. Food and Drug Administration (FDA) has agreed to a Special Protocol Assessment (SPA) Agreement Modification for the Company’s pivotal Phase 3 SOL clinical trial of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).